Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01415882
Recruitment Status : Recruiting
First Posted : August 12, 2011
Last Update Posted : December 5, 2019
National Cancer Institute (NCI)
Janssen Scientific Affairs, LLC
Information provided by (Responsible Party):
Mayo Clinic